Northern Trust Corp Purchases 9,994 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT)

Northern Trust Corp boosted its position in Galectin Therapeutics Inc. (NASDAQ:GALT) by 4.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 244,274 shares of the company’s stock after purchasing an additional 9,994 shares during the quarter. Northern Trust Corp owned about 0.39% of Galectin Therapeutics worth $315,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in GALT. Sovran Advisors LLC bought a new stake in Galectin Therapeutics in the 4th quarter valued at $240,000. Retirement Guys Formula LLC raised its holdings in Galectin Therapeutics by 143.4% in the 4th quarter. Retirement Guys Formula LLC now owns 155,343 shares of the company’s stock valued at $200,000 after acquiring an additional 91,526 shares in the last quarter. LPL Financial LLC raised its holdings in Galectin Therapeutics by 69.6% in the 4th quarter. LPL Financial LLC now owns 138,928 shares of the company’s stock valued at $179,000 after acquiring an additional 57,020 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Galectin Therapeutics by 94.9% in the 4th quarter. JPMorgan Chase & Co. now owns 59,693 shares of the company’s stock valued at $77,000 after acquiring an additional 29,065 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new position in Galectin Therapeutics in the 4th quarter valued at $37,000. 11.68% of the stock is currently owned by institutional investors.

Galectin Therapeutics Price Performance

Shares of NASDAQ GALT opened at $1.31 on Monday. The stock has a market capitalization of $82.91 million, a PE ratio of -1.79 and a beta of 0.62. The business has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.53. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $3.17.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.05. On average, equities analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Galectin Therapeutics in a report on Wednesday, April 2nd.

Galectin Therapeutics Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.